Navigation Links
Cepheid Announces Preliminary 2008 Fourth Quarter and Full Year Revenue Results
Date:1/13/2009

ntial growth in clinical product sales, and demand for certain products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from the company's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the fact that the audit for 2008 has not yet been completed, and therefore could have audit-related adjustments; the impact of the significant global economic downturn on the company's target markets; success in increasing direct sales and the effectiveness of new sales personnel; the performance and market acceptance of new products; sufficient customer demand; our ability to develop and complete clinical trials successfully in a timely manner for new products; uncertainties related to the FDA regulatory and European regulatory processes; the level of testing at clinical customer sites; changes in the protocols or levels of testing for MRSA and other Healthcare Associated Infections (HAIs); the company's ability to successfully introduce and sell products in clinical markets other than HAIs; the mix of products sold; the rate of environmental biothreat testing conducted by the USPS, which will affect the amount of consumable products sold to the USPS; unforeseen development and manufacturing problems; the potential need for additional intellectual property licenses for tests and other products and the terms of such licenses; lengthy sales cycles in certain markets; the company's reliance on distributors in some regions to market, sell and support its products; the impact of competitive products and pricing; and the company's ability to manage geographically-dispersed operations. Readers should also refer to the section entitled "Risk Factors" in Cepheid's Annual Report on Form 10-K for 2007 and its other reports filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Cepheid
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cepheid to Webcast Upcoming Financial Presentations
2. Cepheid Accelerates Direct Sales Channel in UK With Pending Acquisition of Medical Distributor Stretton Scientific
3. Cepheid Reports Third Quarter Revenue of $44.9 Million
4. Results of United Kingdom MRSA Surveillance Program Using Cepheid GeneXpert(R) System Demonstrate Benefits of Rapid Testing
5. Cepheid Molecular Diagnostic Test for MRSA and S. aureus Categorized Moderate Complexity by FDA
6. Cepheid Schedules Fiscal 2008 Third Quarter Financial Results Announcement and Webcast
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Cepheid Receives FDA Clearance for First Rapid On-Demand Molecular Diagnostic Test for MRSA and S. aureus
9. Cepheid to Webcast Upcoming Financial Presentations
10. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
11. Cepheid Reports Second Quarter Revenue of $42.1 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... 2015  Vermillion, Inc. (NASDAQ: VRML ), a ... that Herbert Fritsche , Ph.D., the Lab Director ... recipient of the 2015 Abbott Award, given by the ... contributions to the field of basic or clinical oncology. ... th in Zakopane, Poland . ...
(Date:9/3/2015)... ... September 03, 2015 , ... Park Systems announced ... Sept. 17, 2015 at 9am PST. The webinar will focus on the methods and ... as 3D printing, additive manufacturing is a broad term that encompasses “addition or fusion” ...
(Date:9/2/2015)... 2, 2015 Research and Markets ... of Jain PharmaBiotech,s new report "Nanobiotechnology ... offering. An increasing use ... industries is anticipated. Nanotechnology will be applied ... from formulations for optimal delivery to diagnostic ...
(Date:9/2/2015)... ... September 02, 2015 , ... The wet ... use of special anti-vascular endothelial growth factor agents given by injection into the ... not have a scientific protocol for the many millions diagnosed with it. AMD ...
Breaking Biology Technology:Vermillion Announces Dr. Herbert Fritsche as Recipient of the 2015 Abbott Award from the International Society of Oncology and Biomarkers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 2Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 3Park Systems Announces Webinar on 3D Printing and Additive Manufacturing for Nano-Scientists, Researchers in Nanotechnology and Engineers 4Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... conference call and webcast on Wednesday, October 28, at 5:00 ... , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay Dial-in ...
... Calif., Sept. 30 MacuSight, a developer of ... conditions, today provided a clinical development update for Perceiva, the ... patient enrollment in four ongoing Phase 2 clinical trials of ... the first half of 2010. All four studies are ...
... a number of key issues such as land use and ... global use of biofuels is excepted to more than double ... released today by Hart,s Global Biofuels Center. Leading the expansion ... use of more than 35%. Brazil will grow domestic supplies ...
Cached Biology Technology:BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 2MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 3MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 4MacuSight(R) Provides Clinical Development Update for Perceiva(TM) 5Global Biofuels Growth to Double by 2015 2Global Biofuels Growth to Double by 2015 3Global Biofuels Growth to Double by 2015 4
(Date:8/4/2015)... Research and ... addition of the "Digital Forensics Market ... (Computer Forensics, Network Forensics, Mobile Device Forensics, ... and Region - Global Forecast to 2020" ... By Component (Hardware, Software, and Service), Sub-Segment ...
(Date:7/31/2015)... -- Den 10. internationale konference om Genomik (ICG-10, ... 25. oktober i Shenzhen , Kina. ... år. Siden starten i 2006 er ICB blevet en ... er en af de mest dynamiske, entusiastiske og sjove ... gennembrud og fremskridt inden for ,omik,-forskning, som yderligere vil ...
(Date:7/31/2015)... La 10e Conférence internationale sur la ... le BGI du 22 au 25 octobre 2015 ... La conférence célèbre son 10e anniversaire ... est devenue l,une des réunions annuelles mondiales les ... c,est aussi la plus dynamique, la plus enthousiaste ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... in the prestigious PLoS One journal changes our ... researchers found that degenerative changes and loss of vision are ... autophagy, in the fundus of the eye. The results ... of AMD, which currently lacks an efficient treatment. The University ...
... Monday following a big football game, fans of the ... and sugars, whereas supporters of the winning team opt ... Psychological Science , a journal of the Association ... that sport outcomes influence reckless driving, heart attacks, and ...
... 20, 2013  Today BluStor PMC, Inc. unveiled the ... protects the full stream of mobile security: device, ... what,s possible using BluStor, the company has launched ... http://www.blustor.com/whatspossible.php . (Logo:   http://photos.prnewswire.com/prnh/20130820/PH66368LOGO ) ...
Cached Biology News:Research breakthrough: Impaired autophagy associated with age-related macular degeneration 2For disappointed sports fans, defeats increase consumption of fat and sugar 2BluStor Introduces the World's First Platform to Protect the Full Stream of Mobile Security: Device, User, And Data 2
... DNA Polymerase I Large (Klenow) Fragment, ... that lacks both the 5´→3´ and the ... coli DNA Polymerase I (1,2). It is ... in strand displacement amplification (5). Klenow Fragment, ...
... one of several isoprostanes produced from arachidonic acid ... vasoconstrictor in the rat. 8-iso PGE2 inhibits U-46619 ... 0.5 and 5 µM, respectively. When infused into ... concentration of 4 mg/kg/min, 8-iso PGE2 decreases the ...
DNA Polymerase I Large (Klenow) Fragment is a DNA polymerase that lacks the 5'Cut Site3' exodeoxyribonuclease activity of intact DNA Polymerase I but it contains the 3'Cut Site5' exodeoxyribonuclease...
... Centra-CL5R multi-purpose centrifuge offers both high-speed ... assortment of rotor options, making it ... applications., Maximum Versatility , High-speed ... angle rotors or high-volume (4 x 250mL) ...
Biology Products: